Key clinical point: Avadomide monotherapy was well tolerated and demonstrated preliminary clinical efficacy for relapsed/refractory DLBCL.
Major finding: Treated patients with relapsed/refractory DLBCL had a 29% overall response rate, including 11% complete response.
Study details: Analysis of 84 patients avadomide monotherapy-treated patients with relapsed/refractory DLBCL.
Disclosures: The authors include employees of Bristol-Myers Squibb, which produces avadomide, and others reported funding from various pharmaceutical companies.
“Novel therapeutic strategies are needed in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) due to poor outcomes in this patient population. The cereblon-modulating agent avadomide (CC-122) impacts the immune response and results in decreased cell growth and increased cell death in DLBCL. Drs. Carpio et al report on 97 patients with relapsed/refractory DLBCL patients treated with continuous or intermittent dosing schedules of avadomide. The most common adverse events were cytopenias (including febrile neutropenia) and infections, though only resulted in discontinuation in 10% of patients. Of the patients with de novo DLBCL, the overall response rate of 29% and complete response rate of 11% are promising. The combination of avadomide with other targeted therapies will be investigated in forthcoming clinical trials.”
Sarah Rutherford, MD
Assistant Professor of Medicine, Weill Cornell Medicine
Disclosures: Dr. Rutherford serves as a consultant for AstraZeneca, BMS/Celgene/Juno, Karyopharm, Kite Pharma.
Carpio C et al. Blood. 2020;135(13): 996–1007.